The Role of Home-Visitation Programs in Improving Health Outcomes for Children and Families

,

doi:10.1542/peds.101.3.486

Cited by 108 publications

(6 citation statements)

References 17 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests the need for home visitation/follow-up on phone after DAMA as it may help reduce negative consequences of DAMA and also afford clinicians the opportunity to know the outcomes of these cases. Home visitation is an intervention strategy which has been found to be associated with improvement in health outcomes (39,40). Hence, home visitation programs/follow-up on phone should be instituted or strengthened in pediatric health care services.…”

Section: Discussionmentioning

confidence: 99%

Pediatric Discharges Against Medical Advice: A Review of Cases in Ado-Ekiti, Nigeria

et al. 2021

View full text Add to dashboard Cite

Background: Knowledge of the profile of pediatric discharge against medical advice (DAMA) may help design interventions to reduce its prevalence. Objectives: This study aimed to assess the profile of pediatric DAMA at Ekiti State University Teaching Hospital (EKSUTH), Ado-Ekiti, Ekiti State, Nigeria. Methods: This retrospective cross-sectional descriptive study included all pediatric cases of DAMA from January 2012 to December 2018. Relevant information was extracted from the patients’ case notes. Data was analyzed using the statistical package for social sciences (SPSS) version 23. Results: The overall prevalence of pediatric DAMA was 3.8%. Of the 233 pediatric DAMA with complete information, 127 (54.5%) were males. Severe malaria (27.3%) was the most common diagnosis among DAMA cases at the children emergency ward (CEW), while severe perinatal asphyxia (25.0%) and neonatal sepsis (25.0%) were the most common at the special care baby unit (SCBU). Only 1 (0.4%) patient was enrolled in the National Health Insurance Scheme (NHIS). Moreover, 43 (18.5%) parents took DAMA due to financial constraints, and 55% of the patients had their DAMA form signed by their fathers. In addition, among the patients who referred for follow-up, 11 (4.7%) patients fully recovered, 2 (0.8%) recovered with disability, 1 (0.4%) was readmitted, and 1 (0.4%) died. The highest and lowest DAMA rates were in the months of May and December, respectively. Patients aged under five years old who took DAMA significantly had infectious diseases compared to older age groups (P

show abstract

Section: Discussionmentioning

confidence: 99%

Pediatric Discharges Against Medical Advice: A Review of Cases in Ado-Ekiti, Nigeria

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This survey was not intended to become a consensus conference or issue guidelines but rather to evaluate and summarize common clinical practice in Europe and attitudes of pediatric endocrinologists in Europe. It is clear that while it is important to know about physicians’ attitudes, one should also know about the perception of height, acceptance of therapy and psychosocial functioning in the hypogonadal girls and their families in different populations [10, 11, 12, 13, 14]. Only few such surveys involving the patients themselves have been conducted [11].…”

Section: Discussionmentioning

confidence: 99%

“…Only few such surveys involving the patients themselves have been conducted [11]. Adjustments of estrogen and growth hormone doses over time [10, 12]have been proposed. Age at which therapies should start is seen under different aspects: cultural, metabolic, auxologic and psychosocial issues prevail while even personal views and perceptions do influence a physician’s recommendations [12, 13, 14, 15, 16, 17, 18].…”

Section: Discussionmentioning

confidence: 99%

Induction of Puberty in the Hypogonadal Girl – Practices and Attitudes of Pediatric Endocrinologists in Europe

Kieß¹,

Conway

Ritzén

et al. 2002

Horm Res Paediatr

View full text Add to dashboard Cite

The management of children and adolescents with hypogonadism and in particular the induction of puberty in the hypogonadal girl is subject to controversy. Therefore, under the auspices and through organization of the Drugs and Therapeutics Committee of the European Society of Paediatric Endocrinology (ESPE), an interactive voting session and workshop was held at the 39th ESPE Annual Meeting in Brussels to discuss these topics. Common practice in Europe and attitudes of pediatric endocrinologists in Europe were questioned and recorded in the 1.5-hour program. We now report on some of the results of the questionnaires and discussions of that session to further the discussion on and knowledge of current concepts of induction of puberty in the hypogonadal girl in Europe. It became clear from the data accumulated here that the start of treatment, the aims of therapy and the modalities of how to treat the hypogonadal girl vary amongst pediatric endocrinologists in Europe. For example, a chronological age ≧11 years was considered appropriate for the start of estrogen therapy by 40.4% (out of 188 answers), while 47.8 and 7.5% felt that a chronological age ≧13 and ≧15 years respectively was appropriate. In respect to the form and route of estrogen administration, the audience was asked for their common estrogen replacement practice: 31.9% used oral 17β-estradiol treatment, while 10% would prescribe 17β-estradiol transdermal patches. Another 12.2% would recommend conjugated estrogens (e.g. Premarin^®) orally, 4.8% use oral estradiol valerate and 39.3% ethinylestradiol orally. Only 1.8% out of 229 physicians answering were undecided. In addition, counseling of patients and their families is quite variable and perceptions for example regarding potential pregnancies in affected women are also not uniform. In this report the authors do not want to provide their own personal views but rather reflect current practice in Europe. It is hoped that a more uniform picture will emerge once European and international guidelines on how to treat the girl with hypogonadism will be available and even more discussions amongst doctors from different countries have been led.

show abstract

“…The strategy of using estrogen replacement to facilitate optimal growth in such girls has been discussed elsewhere [6, 7, 8, 9, 10]. Thus determining an estrogen replacement schedule for optimal concurrent use with growth hormone therapy has become a practical issue for patients with TS [6]. …”

Section: Introductionmentioning

confidence: 99%

The Uterine Length in Women with Turner Syndrome Reflects the Postmenarcheal Daily Estrogen Dose

et al. 2003

View full text Add to dashboard Cite

Aim: To evaluate the effects of estrogen substitution on the uterine development in patients with Turner syndrome. Method: 57 women, aged 18.1–41.5 years, were treated with estrogen from puberty induction. Results: In 21 women (37%), the uterus developed to >65 mm in length. The daily estrogen dose correlated with both uterine length (r = 0.29; p < 0.05) and Tanner breast stage (r = 0.44; p < 0.001). A negative correlation between age at artificial menarche and uterine length was found (r = –0.29; p < 0.05). The endometrium thickness was greater in women with an uterus length >65 mm (p < 0.05). In 50% of the women (18 were evaluated), an adult-shaped uterus developed. Previous growth hormone therapy (n = 32) had no impact on the uterus length. Conclusions: The uterine development was suboptimal in most patients. Further investigation is needed to optimize estrogen therapy for uterine development in patients with Turner syndrome.

show abstract

The Role of Home-Visitation Programs in Improving Health Outcomes for Children and Families

Cited by 108 publications

References 17 publications

Pediatric Discharges Against Medical Advice: A Review of Cases in Ado-Ekiti, Nigeria

Pediatric Discharges Against Medical Advice: A Review of Cases in Ado-Ekiti, Nigeria

Induction of Puberty in the Hypogonadal Girl – Practices and Attitudes of Pediatric Endocrinologists in Europe

The Uterine Length in Women with Turner Syndrome Reflects the Postmenarcheal Daily Estrogen Dose

Contact Info

Product

Resources

About